Can a novel sleeping pill help Jingxin shed its generic label?
The pharmaceutical firm has gained traction with its first new drug and is seeking funds for further innovation, but its mainstay generics business is under pressure Key Takeaways: Jingxin Pharmaceutical…
What an AI breach of WeChat and Jollibee’s listing choice mean for U.S.-Asia tech and capital
"If you want to ensure the success of a company that is still very much regional Southeast Asia when going to market, it's probably a bit easier in Hong Kong…
Robot vacuum component maker Camsense launches $78 million Hong Kong IPO
Robot vacuum spatial perception component maker Shenzhen Camsense Technologies Co. Ltd. (6802.HK) launched its Hong Kong IPO on Tuesday, offering shares at HK$58.85 each. The company expects to raise net…
Ligent Technologies launches $700 million Hong Kong IPO
Optical communications product maker Ligent Technologies Inc. (9856.HK) launched its Hong Kong IPO on Monday, aiming to raise about HK$5.45 billion ($695 million) by selling 172 million shares to investors…
Salubris refiles for Hong Kong IPO as generics lose steam
The producer of cardiovascular drugs is accelerating its shift towards innovative pharmaceuticals, under pressure from price cuts and expiring patents Key Takeaways: Salubris built its early success on generics, but…
Excelland Robotics leaps in trading debut despite tepid international interest
Shares of robotics manufacturer Excelland Robotics (Wuxi) Co. Ltd. (3231.HK) opened 142% above their IPO price in their trading debut on Wednesday, and climbed through the morning session to end…
Mech-Mind debuts as Hong Kong’s first ‘embodied intelligence eye-brain-hand’ stock
The company, which serves more than 100 Fortune Global 500 companies, derives over half its revenue overseas, and counts Baillie Gifford among its cornerstone investors By Teri Yu Intelligent robot-component…
Recent Articles
RELATED ARTICLES
-
Salubris refiles for Hong Kong IPO as generics lose steam
002294.SHE
-
CSPC Innovation pursues Hong Kong IPO as parent profits shrink
300765.SHE
-
Its revenue surging, can co-built fleets help Pony AI drive to profits?
2026.HKPONY.US
-
JBM Healthcare gets bitter pill from investors on anemic performance
2161.HK
-
Drug setback leaves Ascletis with an all-in bet on weight loss
1672.HK
- Insilico revenue soars above $100 million on AI drug partnerships
-
Cancer drug sales power up Kelun-Biotech’s profit engine
6990.HK
